Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Corbus Pharmaceuticals Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has returned 15.36% so far this year and 76.84% over the past 12 months. Over the last ten years, CRBP has returned -16.05% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Nov 11, 2014, CRBP's average daily return is +0.18%, while the average monthly return is +3.31%. At this rate, your investment would double in approximately 1.8 years.

Historically, 45% of months were positive and 55% were negative. The best month was Jan 2024 with a return of +338.6%, while the worst month was Sep 2020 at -80.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.

On a daily basis, CRBP closed higher 45% of trading days. The best single day was Jan 26, 2024 with a return of +249.4%, while the worst single day was Sep 8, 2020 at -75.9%.

Corbus Pharmaceuticals Holdings, Inc. has an annualized alpha of 35.18%, beta of 1.31, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 12, 2014.

• This stock participated in 234.45% of S&P 500 Index downside but only 200.83% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRBP ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Corbus Pharmaceuticals Holdings, Inc. (CRBP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Corbus Pharmaceuticals Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Corbus Pharmaceuticals Holdings, Inc. was 99.31%, occurring on Mar 10, 2023. The portfolio has not yet recovered.

The current Corbus Pharmaceuticals Holdings, Inc. drawdown is 96.98%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Corbus Pharmaceuticals Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Corbus Pharmaceuticals Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.